These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 27141346)

  • 1. Co-inhibition of colony stimulating factor-1 receptor and BRAF oncogene in mouse models of BRAF
    Ngiow SF; Meeth KM; Stannard K; Barkauskas DS; Bollag G; Bosenberg M; Smyth MJ
    Oncoimmunology; 2016 Mar; 5(3):e1089381. PubMed ID: 27141346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition.
    Mok S; Tsoi J; Koya RC; Hu-Lieskovan S; West BL; Bollag G; Graeber TG; Ribas A
    BMC Cancer; 2015 May; 15():356. PubMed ID: 25939769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CSF1/CSF1R Axis Blockade Limits Mesothelioma and Enhances Efficiency of Anti-PDL1 Immunotherapy.
    Magkouta SF; Vaitsi PC; Pappas AG; Iliopoulou M; Kosti CN; Psarra K; Kalomenidis IT
    Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34067348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural killer cells are essential for the ability of BRAF inhibitors to control BRAFV600E-mutant metastatic melanoma.
    Ferrari de Andrade L; Ngiow SF; Stannard K; Rusakiewicz S; Kalimutho M; Khanna KK; Tey SK; Takeda K; Zitvogel L; Martinet L; Smyth MJ
    Cancer Res; 2014 Dec; 74(24):7298-308. PubMed ID: 25351955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T cell-induced CSF1 promotes melanoma resistance to PD1 blockade.
    Neubert NJ; Schmittnaegel M; Bordry N; Nassiri S; Wald N; Martignier C; Tillé L; Homicsko K; Damsky W; Maby-El Hajjami H; Klaman I; Danenberg E; Ioannidou K; Kandalaft L; Coukos G; Hoves S; Ries CH; Fuertes Marraco SA; Foukas PG; De Palma M; Speiser DE
    Sci Transl Med; 2018 Apr; 10(436):. PubMed ID: 29643229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PLX3397 inhibits the accumulation of intra-tumoral macrophages and improves bromodomain and extra-terminal inhibitor efficacy in melanoma.
    Erkes DA; Rosenbaum SR; Field CO; Chervoneva I; Villanueva J; Aplin AE
    Pigment Cell Melanoma Res; 2020 Mar; 33(2):372-377. PubMed ID: 31696640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rational combination of an immune checkpoint inhibitor with CSF1R inhibitor-loaded nanoparticle enhances anticancer efficacy.
    Ramesh A; Malik V; Ranjani HA; Smith H; Kulkarni AA
    Drug Deliv Transl Res; 2021 Dec; 11(6):2317-2327. PubMed ID: 34365577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of CSF-1 receptor improves the antitumor efficacy of adoptive cell transfer immunotherapy.
    Mok S; Koya RC; Tsui C; Xu J; Robert L; Wu L; Graeber T; West BL; Bollag G; Ribas A
    Cancer Res; 2014 Jan; 74(1):153-161. PubMed ID: 24247719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy.
    Priceman SJ; Sung JL; Shaposhnik Z; Burton JB; Torres-Collado AX; Moughon DL; Johnson M; Lusis AJ; Cohen DA; Iruela-Arispe ML; Wu L
    Blood; 2010 Feb; 115(7):1461-71. PubMed ID: 20008303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRAF inhibition alleviates immune suppression in murine autochthonous melanoma.
    Steinberg SM; Zhang P; Malik BT; Boni A; Shabaneh TB; Byrne KT; Mullins DW; Brinckerhoff CE; Ernstoff MS; Bosenberg MW; Turk MJ
    Cancer Immunol Res; 2014 Nov; 2(11):1044-50. PubMed ID: 25183499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CSF1R Is Required for Differentiation and Migration of Langerhans Cells and Langerhans Cell Histiocytosis.
    Lonardi S; Scutera S; Licini S; Lorenzi L; Cesinaro AM; Gatta LB; Castagnoli C; Bollero D; Sparti R; Tomaselli M; Medicina D; Calzetti F; Cassatella MA; Facchetti F; Musso T; Vermi W
    Cancer Immunol Res; 2020 Jun; 8(6):829-841. PubMed ID: 32238382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of the CSF1R inhibitor PLX3397 on remyelination of corpus callosum in a cuprizone-induced demyelination mouse model.
    Tahmasebi F; Pasbakhsh P; Mortezaee K; Madadi S; Barati S; Kashani IR
    J Cell Biochem; 2019 Jun; 120(6):10576-10586. PubMed ID: 30628737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective BRAF inhibition decreases tumor-resident lymphocyte frequencies in a mouse model of human melanoma.
    Hooijkaas A; Gadiot J; Morrow M; Stewart R; Schumacher T; Blank CU
    Oncoimmunology; 2012 Aug; 1(5):609-617. PubMed ID: 22934253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer.
    Xu J; Escamilla J; Mok S; David J; Priceman S; West B; Bollag G; McBride W; Wu L
    Cancer Res; 2013 May; 73(9):2782-94. PubMed ID: 23418320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Silence of a dependence receptor CSF1R in colorectal cancer cells activates tumor-associated macrophages.
    Zhu M; Bai L; Liu X; Peng S; Xie Y; Bai H; Yu H; Wang X; Yuan P; Ma R; Lin J; Wu L; Huang M; Li Y; Luo Y
    J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36600555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PLX3397 treatment inhibits constitutive CSF1R-induced oncogenic ERK signaling, reduces tumor growth, and metastatic burden in osteosarcoma.
    Smeester BA; Slipek NJ; Pomeroy EJ; Laoharawee K; Osum SH; Larsson AT; Williams KB; Stratton N; Yamamoto K; Peterson JJ; Rathe SK; Mills LJ; Hudson WA; Crosby MR; Wang M; Rahrmann EP; Moriarity BS; Largaespada DA
    Bone; 2020 Jul; 136():115353. PubMed ID: 32251854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.
    Hu-Lieskovan S; Mok S; Homet Moreno B; Tsoi J; Robert L; Goedert L; Pinheiro EM; Koya RC; Graeber TG; Comin-Anduix B; Ribas A
    Sci Transl Med; 2015 Mar; 7(279):279ra41. PubMed ID: 25787767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma.
    Homet Moreno B; Mok S; Comin-Anduix B; Hu-Lieskovan S; Ribas A
    Oncoimmunology; 2016 Jul; 5(7):e1052212. PubMed ID: 27622011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PLX3397, a CSF1 receptor inhibitor, limits allotransplantation-induced vascular remodelling.
    Almonte VM; Uriyanghai U; Egaña-Gorroño L; Parikh D; Oliveira-Paula GH; Zhang J; Jayakumar S; Riascos-Bernal DF; Sibinga NES
    Cardiovasc Res; 2022 Sep; 118(12):2718-2731. PubMed ID: 34478521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EGFR blockade prevents glioma escape from BRAFV600E targeted therapy.
    Yao TW; Zhang J; Prados M; Weiss WA; James CD; Nicolaides T
    Oncotarget; 2015 Sep; 6(26):21993-2005. PubMed ID: 26023796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.